In summary, the data presented in this study clearly showed that by increasing the lysosomal pH in cancer cells and fostering the transition of M2-TAMs to M1 macrophages to induce CD8+ T cell anti-tumour effects, HCQ could function as a chemo-sensitizer and immune regulator to enhance the therapeutic effects of NSCLC. The gene discussed is CD8A; the disease is cancer.